SIGA Technologies (SIGA Technologies) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies Debt-to-Equity?

SIGA Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.6 Mil. SIGA Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. SIGA Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $196.9 Mil. SIGA Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SIGA Technologies's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of SIGA Technologies was 0.82. The lowest was -0.23. And the median was 0.00.

SIGA's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.285
* Ranked among companies with meaningful Debt-to-Equity only.

SIGA Technologies Debt-to-Equity Historical Data

The historical data trend for SIGA Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Debt-to-Equity Chart

SIGA Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.82

SIGA Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of SIGA Technologies's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SIGA Technologies's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's Debt-to-Equity falls into.

SIGA Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SIGA Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.564	+	0)	/	196.859
	=	0.00

SIGA Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.564	+	0)	/	196.859
	=	0.00

SIGA Technologies (NAS:SIGA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SIGA Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SIGA Technologies (SIGA Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 East 62nd Street, New York, NY, USA, 10065

Website

http://www.siga.com

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.

Executives

Evan A. Knisely	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr.	director	4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal	director	30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky	director	35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi	director	35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan	director	C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii	officer: Chief Executive Officer	7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire	officer: Executive VP & CFO	C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas	director	35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane	director	77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby	officer: Chief Scientific Officer	SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer	director	1100 N GLEBE ROAD, ARLINGTON VA 22201